Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panobacumab - Aridis Pharmaceuticals

Drug Profile

Panobacumab - Aridis Pharmaceuticals

Alternative Names: Aerumab; AERUMAB 11; AR 101 (anti-Pa mAb) - Aridis Pharmaceuticals; AR-101 - Aridis Pharmaceuticals; KBPA-101

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Berna Biotech
  • Developer Aridis Pharmaceuticals
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 30 Sep 2019 Panobacumab licensed to the Serum Institute of India, in regions outside of USA, Europe, Canada, UK, China, Australia, New Zealand and Japan (9275697​)
  • 09 Aug 2019 Panobacumab is still in Clinical development for Nosocomial pneumonia in Switzerland, Belgium, France and Greece (IV) (Aridis Pharmaceuticals pipeline, August 2019)
  • 30 Jul 2019 Aridis Pharmaceuticals enters an option agreement with Serum International for panobacumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top